Solutions

Online Inquiry

* Your Name

* Phone Number

* E-mail Address

* Services Interested

Project Description

* Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Bronchitis

Bronchitis is a type of respiratory disease where the bronchial tubes, which are the passages for air to and from the lungs, are inflamed. It may be acute, as in the case of illness caused by viruses, or chronic when there is persistent inflammation of the bronchial passages due to smoking. Protheragen develops MyD88-targeted therapies for Bronchitis, addressing innate immune hyperactivation and inflammation driving airway remodeling and infection-induced exacerbations.

Fig.1 Predicted configuration of TJ-M2010-5 binding
to the MyD88 in box3. (Johnson et al., 2019)

Overview of Bronchitis

Bronchitis entails the inflammation of the bronchi, accompanied by coughing, mucus over secretion, and difficulty in breathing. There are two primary types: acute bronchitis which results from infections such as rhinovirus and influenza, and chronic bronchitis, a subgroup of chronic obstructive pulmonary disease (COPD) associated with prolonged irritants such cigarette smoke or air pollution. It is primarily associated with neutrophilic inflammation, goblet cell hyperplasia, and breakdown of mucociliary clearance which in turn is caused by a VTEG altered immune response such as TLR4/MyD88 oxidative signaling.

Pathogenesis of Bronchitis

Acute and chronic bronchitis differentiates in its pathogenesis with infections in acute cases and persistent irritants in chronic forms. Pathways triggered by Acute Disease Bronchitis begin with innate immunity marking inflammation through Toll-like receptor engagement and MyD88 pathway signaling. This cascade is marked with the inflammation cycle of molecules, symptom generation of excessive mucus along with bronchiolar narrowing.

MyD88-Targeted Therapeutic Development for Bronchitis

Small Molecule Inhibitors

Development of small molecules that target direct MyD88 dimerization interrupts MyD88 function and instead, targets the MyD88 pathway's downstream kinases like IRAK4. Therefore, these inhibitors will target inflammatory signals triggered by TLRs and IL-1Rs in the airway. These models have shown success in preclinical trials by controlling bronchitis exacerbation inflammation.

Other Therapeutic Modalities

Peptide-based inhibitors of MyD88 signaling pathways provide non-Myd88 dependent strategies. Approaches that act on specific upstream TLRs that signal through MyD88 are being developed in the context of respiratory inflammation. These various types of molecules can be used to target the MyD88 pathway to alter bronchial inflammation control.

Our Services

Protheragen develops advanced disease models for Bronchitis and offers MyD88-targeted therapeutic discovery. Our platform integrates lung-specific in vitro and in vivo models for high-throughput screening of MyD88 signaling modulators, TLR/IL-1R-driven airway inflammation pathways, and mucus hypersecretion mechanisms.

Therapeutic Discovery Platform for Bronchitis

Protheragen's MyD88 discovery platform for Bronchitis combines immune-respiratory crosstalk models to address disrupted innate-adaptive immune interactions in chronic airway inflammation. Through novel inhibitors, degraders, or biologics, the platform achieves preclinical validation by targeting MyD88-dependent cytokine networks that drive mucus overproduction and airway remodeling, while synergizing with standard therapies.

Disease Models Development for Bronchitis

Protheragen offers a full range of services for preclinical modeling of Bronchitis, featuring cell-based models, organoid models, and animal models that capture the complex pathophysiology of this immune-mediated respiratory disease, including airway inflammation, mucus hypersecretion, and epithelial barrier dysfunction.

Cell-based & Organoid models

Primary Human Bronchial Epithelial Cells
Immune Cell-Airway Co-Culture Systems
Human Bronchial Organoids
Infection-Induced Mucus Organoids

Animal Models Development

Cigarette Smoke Exposure Models
Elastase-Induced Bronchitis Models
Viral Infection Models
Ovalbumin/LPS-Challenged Models

Through the treatment options framework for Protheragen, MyD88 related diseases are pursued aggressively. This is done by building comprehensive proposal tools ranging from disease model development, pharmacokinetics and drug safety evaluation, and other focus areas including investigator-initiated trials that aim to expedite the primary assessment stage.

If you are interested in our services, please don't hesitate to contact us.

References

Johnson, A. N., et al. "Myd88 Regulates a Prolonged Adaptation Response to Environmental Dust Exposure-Induced Lung Disease." Respir Res 21.1 (2020): 97.
Yang, M., et al. "A Novel Myd88 Inhibitor Attenuates Allograft Rejection after Heterotopic Tracheal Transplantation in Mice." Transpl Immunol 53 (2019): 1-6.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.